Faculty Bibliography

OBJECTIVE: This article explores recent developments in PET and MRI, separately or combined, for assessing metastatic lymph nodes in patients with head and neck cancer. CONCLUSION: The synergistic role of PET and MRI for imaging metastatic lymph nodes has not been fully explored. To facilitate the understanding of the areas that need further investigation, we discuss potential mechanisms and evidence reported so far, as well as future directions and challenges for continued development and clinical research.

Objectives 1. Review the existing literature on radio-guided surgery using conventional nuclear medicine and PET radiopharmaceuticals, gamma cameras and PET/CT scanners. 2. Learn about a new technique using PET/MR in the pre-operative localization of lesions prior to radio-guided surgery. Background: Radiopharmaceuticals have been used in conjunction with gamma cameras and PET scanners to localize tumor deposits prior to radio-guided surgery using intra-operative probes, often assisted by portable cameras. One disadvantage of PET/CT scanners is that pre-operative lesion localization may require multiple CT acquisitions, thus increasing radiation exposure to the patient. This exhibit will briefly review conventional techniques to localize non-palpable tumor deposits before surgery using nuclear medicine techniques, and will demonstrate in detail a new method of FDG PET/MR-guided pre-operative lesion localization prior to radio-guided surgery. A major focus of this review will be on case examples of patients with non-palpable subcutaneous FDG-avid tumor deposits for which surgical resection is the gold standard for management. After confirming uptake on whole-body PET/CT, patients are referred to the PET/MR Department on the day of surgery. FDG is injected and lesions are imaged on a Siemens Biograph mMR PET/MR scanner using conventional static PET and STIR MR sequences. A vitamin E marker is used in conjunction with an FDG point source to mark the tumor location on the skin, and the best orientation for surgical dissection and patient positioning is reviewed. A PET probe is used intra-operatively to assist in identification of tumor deposits. (Figure Presented)

Objectives Learning objectives: 1. To review morphologic and functional imaging changes on PET/CT following various lymphoma treatment regimens. 2. To evaluate various circumstances under which the morphologic and functional imaging changes are concordant or discordant. The World Health Organization International Classification of Disease (2008) identifies numerous types of lymphoma based on histopathologic, immunohistochemical, cytogenetic, and molecular analyses. Practically, only a few subtypes of lymphoma account for the majority of cases such as diffuse large B cell lymphoma. Many of the lymphomas are potentially curable when treated with chemotherapy alone or in combination with radiation therapy; remainder are only potentially curable with stem cell transplantation. Nowadays PET/CT imaging is crucial in staging and treatment response assessment for most of these lymphomas. On PET/CT there are multiple imaging patterns of the treatment response. Additionally, there have been continuing efforts to establish the response criteria on PET/CT to help aid optimal treatment decisions. This exhibit is designed to review and understand the various imaging patterns observed on the PET/CT on treatment of the lymphoma following simple and complex treatment regimens

Objectives PET/MR may be used in the evaluation of cognitively impaired patients. There are known quantitative differences between PET images obtained on PET/MR scanners when reconstructed with Dixon-MR, CT-based or atlas-based attenuation correction (AC) maps. This study seeks to assess the impact, if any, of these three-different AC methods on the blinded visual interpretation of regional hypometabolism in patients with cognitive impairment. Methods Forty-five minutes following injection of 10 mCi of FDG, 15 patients with cognitive impairment underwent brain PET/CT. PET/MR scanning with a 10 minute PET acquisition and Dixon MR imaging was subsequently performed on a Siemens Biograph mMR scanner under an IRB-approved protocol, at approximately two hours post-injection. A manufacturer-provided non-product offline reconstruction tool was used to reconstruct PET data obtained from PET/MR with AC based on the patient's own CT images, a Dixon-MR derived AC map and an atlas-based AC map that combined Dixon-MR with a segmentation of bony skull structures. Two nuclear medicine physicians blindly scored brain regions (frontal, temporal, parietal, occipital, precuneus) as normal versus hypometabolic using 2D and 3D images generated by MIM software. Abnormal regions were scored as mild, moderate, or severely hypometabolic (score of 0, 1, 2 or 3 respectively). The hypometabolism scores obtained using the different methods of AC were compared and reader agreement assessed. All statistical tests were conducted at the two-sided 5% significance level using SAS 9.3 (SAS Institute, Cary, NC). Results Regional hypometabolism versus normal metabolism was correctly classified (accuracy) for 150 regions in 15 patients by two readers on atlas- and Dixon-based AC map PET reconstructions (versus CT reference AC) for 94% (90 - 96% c.i.) and 93% (89 - 96% c.i.) of all regions. The averaged sensitivity/specificity for detection of any regional hypometabolism was 95%/94% and 90%/91% for atlas-based and Dixon-based AC maps, respectively, compared to the reference standard CT images. The mean absolute error of regional hypometabolism scores for atlas- and Dixon-based PET reconstructions (versus CT) was 0.25 +/- 0.44 and 0.21 +/- 0.42 . There were no statistically significant differences between the visual assessments. Intra-reader agreement for detection of regional hypometabolism was high, with similar outcome assessments when using atlas- and Dixon-corrected PET data in 93% and 93% of scored regions, respectively. The simple kappa coefficient to assess reader agreement in terms of hypometabolism versus normal regions was 0.82 for atlas- and 0.84 for Dixon-based AC. The weighted kappa coefficient to assess reader agreement in terms of the hypometabolism score was 0.75 for atlas- and 0.77 for Dixon-AC. Conclusions Despite the more accurate FDG SUV quantification with CT-based and atlas-based attenuation correction in brain PET/MR compared to Dixon AC, there were no measureable differences between the three AC methods with respect to visual identification of regional hypometabolism in the evaluation of cognitively impaired patients

PURPOSE: There is considerable controversy over the treatment of medication-related osteonecrosis of the jaw (MRONJ) and growing interest and debate related to the timing, type, technique, and goals of surgical intervention. The specific aim was to evaluate the predictive value of fluorodeoxyglucose (FDG) positron emission tomography (PET) with computed tomography (CT) on healing outcomes in patients undergoing surgery for MRONJ of the mandible. MATERIALS AND METHODS: A retrospective cohort study of 31 patients with 33 MRONJ lesions of the mandible who had undergone surgery using FDG PET-CT was conducted. Data were collected on FDG uptake patterns, healing, follow-up, demographics, lesion characteristics, antiresorptive therapy, and adjunctive therapy. Panoramic and periapical radiographs were used to identify non-restorable teeth and PET-CT images were used to identify sequestra and FDG uptake. Above the mandibular canal, surgery consisted of marginal resection or debridement of clinically involved bone and exposure of clinically uninvolved bone identified by FDG uptake. Below the mandibular canal, mobile segments of bony sequestra were removed, but areas of clinically uninvolved bone with FDG uptake were not. Patients who did not heal underwent segmental resection and reconstruction with rigid fixation and a local or regional soft tissue flap or free fibular flap. The primary predictor variable was the FDG uptake pattern for each patient. The outcome variable was postoperative healing defined by mucosal closure without signs of infection or exposed bone at the time of evaluation. RESULTS: Two risk groups were identified based on FDG uptake pattern. The low-risk group, type A, included 22 patients with activity limited to the alveolus, torus, and basal bone superior to the mandibular canal. The high-risk group, type B, included 11 patients with type A FDG activity with extension inferior to the mandibular canal. Treatment of type A MRONJ lesions was more successful than treatment of type B MRONJ lesions (100 vs 27%; P < .001). Seven of the type B failures were successfully retreated by segmental resection and reconstruction (1 patient refused further treatment). CONCLUSION: These results showed that low-risk FDG PET-CT findings predicted successful healing with surgery above the mandibular canal. In contrast, high-risk FDG findings were associated with a greater than 50% risk of failure for treatment that extended below the mandibular canal. Although these failures suggest that FDG uptake indicates infected tissue, further research is needed to identify which high-risk patients are most likely to benefit from a conservative treatment protocol.

PURPOSE: To assess outcomes of lung nodules missed on simultaneous positron emission tomography and magnetic resonance imaging (PET/MRI) compared to the reference standard PET and computed tomography (PET/CT) in patients with primary malignancy. MATERIALS AND METHODS: In all, 208 patients with primary malignancy undergoing clinically indicated (18 F) fluorodeoxyglucose (FDG) PET/CT followed by PET/MRI were independently reviewed by two readers. Upon review of the thoracic station on PET/MRI and PET/CT, 89 non-FDG avid small lung nodules in 43 patients were detected (by reader 1) only on the CT component of the PET/CT but were not identified on PET/MRI. Overall, 84 of these 89 nodules were examined on follow-up imaging with PET/CT or chest CT. The remaining five nodules had no follow-up imaging but had remote imaging available for comparison. RESULTS: Among the 84 nodules with follow-up, three nodules (3%) in one patient progressed, 10 (12%) nodules partially/completely resolved, whereas 71 nodules (85%) remained stable. The five nodules without follow-up were all stable since prior imaging of over 21 months. CONCLUSION: The vast majority (97%) of small non-FDG avid lung nodules missed on PET/MRI either resolved or remained stable on follow-up, suggestive of benignity. PET/MRI remains a viable alternative imaging modality in oncology patients, despite its low sensitivity in detecting small lung nodules. J. Magn. Reson. Imaging 2015.

Objective. To show that I-131 false-positive results on whole-body scans (WBSs) after thyroidectomy for thyroid cancer may be a result of inflammation unassociated with the cancer. Methods. We performed a retrospective image analysis of our database of thyroid cancer patients who underwent WBS from January 2008 to January 2012 to identify and stratify false positives. Results. A total of 564 patients underwent WBS during the study period; 96 patients were referred for 99 I-131 single-photon emission computed tomography (SPECT/CT) scans to better interpret cryptic findings. Among them, 73 scans were shown to be falsely positive; 40/73 or 54.7% of false-positive findings were a result of inflammation. Of the findings, 17 were in the head, 1 in the neck, 4 in the chest, 3 in the abdomen, and 14 in the pelvis; 1 had a knee abscess. Conclusions. In our series, inflammation caused the majority of false-positive WBSs. I-131 SPECT/CT is powerful in the differentiation of inflammation from thyroid cancer. By excluding metastatic disease, one can properly prognosticate outcome and avoid unnecessary, potentially harmful treatment of patients with thyroid cancer.

OBJECTIVE: This review article explores recent advancements in PET/MRI for clinical oncologic imaging. CONCLUSION: Radiologists should understand the technical considerations that have made PET/MRI feasible within clinical workflows, the role of PET tracers for imaging various molecular targets in oncology, and advantages of hybrid PET/MRI compared with PET/CT. To facilitate this understanding, we discuss clinical examples (including gliomas, breast cancer, bone metastases, prostate cancer, bladder cancer, gynecologic malignancy, and lymphoma) as well as future directions, challenges, and areas for continued technical optimization for PET/MRI.